ADMA Biologics, Inc.
ADMA
$17.02
$0.110.65%
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Net Income | 1,299.42% | 603.25% | 362.28% | -44.25% | 117.22% |
Total Depreciation and Amortization | -7.27% | -2.43% | 3.98% | 8.44% | 12.35% |
Total Amortization of Deferred Charges | -65.05% | -66.96% | -48.16% | 43.19% | -26.51% |
Total Other Non-Cash Items | 14.79% | 9.31% | 2.70% | 1,088.49% | 21.36% |
Change in Net Operating Assets | -520.20% | 267.58% | -95.73% | 100,144.44% | 210.63% |
Cash from Operations | 108.83% | 853.36% | 84.94% | 338.46% | 190.22% |
Capital Expenditure | -39.50% | -136.93% | -20.67% | 68.06% | 77.61% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -45.05% | -171.22% | -21.44% | 62.46% | 77.61% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -1,822,716.09% | 100.00% |
Issuance of Common Stock | 812.02% | -29.87% | -- | -99.99% | -- |
Repurchase of Common Stock | -456.73% | -206.64% | -286.88% | 83.53% | 51.63% |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -15,076,900.00% | -- |
Cash from Financing | -6,221.88% | -250.83% | -122.62% | -162.15% | 149.30% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -113.20% | 741.44% | 65.20% | -144.18% | 166.50% |